The PDHX Knockout Raji Polyclonal Cells product comprises a genetically engineered Raji B lymphocyte population featuring CRISPR/Cas9-mediated disruption of the PDHX gene, which encodes the E3-binding protein of the pyruvate dehydrogenase complex. This polyclonal knockout pool arises from bulk editing and selection, yielding a heterogeneous population of PDHX-deficient cells that enables robust interrogation of pyruvate dehydrogenase complex integrity without clonal isolation artifacts. The loss-of-function model is supplied as a ready-to-use suspension culture, facilitating direct integration into metabolic and oncological research workflows.
The host Raji cell line is a widely employed lymphoblastoid B cell model originally derived from a Burkitt’s lymphoma patient. These Epstein-Barr virus (EBV)-positive suspension cells retain key B lymphocyte characteristics, including antigen presentation capacity and immunoglobulin production, making them a cornerstone system for hematological malignancy studies. Their rapid growth and consistent behavior in culture support reproducible assays of lymphoma biology, while the EBV association provides additional relevance for viral?Clymphoma interplay investigations.
PDHX plays a structural role within the pyruvate dehydrogenase complex by tethering dihydrolipoamide dehydrogenase (DLD, E3) to the dihydrolipoamide acetyltransferase (DLAT, E2) core, a critical step for the oxidative decarboxylation of pyruvate to acetyl-CoA. Disruption of PDHX therefore destabilizes the complex, impairing substrate channeling and reducing acetyl-CoA generation. The PDHX protein interacts directly with DLAT and DLD, and its function is tightly controlled by upstream regulators including pyruvate dehydrogenase kinase isozymes (PDK1?C4), which phosphorylate and inactivate the E1?? subunit, and insulin receptor/PI3K/AKT signaling converging on PDK activity. Hypoxia-inducible factor HIF-1?? transcriptionally upregulates PDK1, linking oxygen availability to PDHX-dependent metabolic flux. Downstream, acetyl-CoA feeds the TCA cycle, ATP production, lipid synthesis, and histone acetylation, while the loss of PDHX shifts metabolism toward glycolysis and alters reactive oxygen species balance.
In the Raji B lymphoma context, ablation of PDHX creates a metabolic vulnerability that mirrors the Warburg effect, where enhanced glycolysis compensates for defective mitochondrial pyruvate oxidation. This polyclonal knockout model directly addresses how B cell malignancies reprogram central carbon metabolism and may reveal dependencies on anaplerotic pathways or redox homeostasis. The EBV-positive lymphoblastoid background further allows examination of how viral factors intersect with metabolic stress responses, providing a platform for dissecting the metabolic underpinnings of lymphoma survival and immune evasion.
Applications of this tool span mitochondrial metabolism research, cancer biochemistry, and metabolic disease modeling. Researchers can employ Seahorse extracellular flux analysis to measure basal and maximal oxygen consumption rates alongside glycolytic proton efflux, validated by pyruvate dehydrogenase enzyme activity assays and Western blotting for PDHX and associated subunits. Targeted metabolomics can profile acetyl-CoA, TCA cycle intermediates, and lactate levels, while glucose uptake and ROS detection assays link metabolic reprogramming to functional outcomes. Integration with CRISPR sequencing confirmation and RT-qPCR for metabolic genes ensures editing and expression validation. The cells are also suitable for high-throughput screening of small-molecule PDH modulators or lymphoma-specific metabolic inhibitors. For additional information on custom applications, please contact Ascent Research.
